Dietary 135-fold cholecalciferol supplementation severely disturbs the endochondral ossification in growing dogs.
The effects of excessive non-toxic dietary Vitamin D(3) supplementation on Ca homeostasis with specific effects on endochondral ossification and skeletal remodeling were investigated in a group of growing Great Dane dogs supplemented with cholecalciferol (Vitamin D(3); HVitD) versus a control group (CVitD) (1350 microg versus 11.4 microg Vitamin D(3) per kilogram diet) from 6 to 21 weeks of age. There were no differences between groups in plasma concentrations of total Ca, inorganic phosphate, growth hormone, and insulin-like growth factor I and no signs of Vitamin D(3) intoxication in HVitD. For the duration of the study in HVitD compared to CVitD, plasma levels of parathyroid hormone (PTH) decreased, calcitonin (CT) increased, 25-hydroxycholecalciferol [25(OH)D(3)] increased 30- to 75-fold, 24,25-dihydroxycholecalciferol [24,25(OH)(2)D(3)] increased 12- to 16-fold, and 1,25-dihydroxycholecalciferol [1,25(OH)(2)D(3)] decreased by approximately 40%. The latter was attributed to the two-fold increased metabolic clearance rate in the HVitD versus CVitD accompanied by the absence of the anabolic effect of PTH on the production of 1,25(OH)(2)D(3). Fractional Ca absorption (alpha) did not differ between groups at 8 and 14 weeks of age, whereas at 20 weeks of age alpha increased by only 16.4% in HVitD compared to CVitD. Excessive non-toxic Vitamin D(3) supplementation resulted in decreased bone remodeling and focal enlargement of the growth plate with morphology resembling those induced by administration of CT. Hypercalcitoninemia and the imbalanced relationship between 1,25(OH)(2)D(3) and 24,25(OH)(2)D(3) are potent candidates for the disturbed endochondral ossification.
Tryfonidou
M A
MA
Department of Clinical Sciences of Companion Animals, Faculty of Veterinary Medicine, Utrecht University, Yalelaan 8, 3584 CM, Utrecht, The Netherlands. M.A.Tryfonidouvet.uu.nl
Holl
M S
MS
Stevenhagen
J J
JJ
Buurman
C J
CJ
Deluca
H F
HF
Oosterlaken-Dijksterhuis
M A
MA
van den Brom
W E
WE
van Leeuwen
J P T M
JP
Hazewinkel
H A W
HA
D015650:24,25-Dihydroxyvitamin D 3 / Q000097:blood; D000375:Aging; D000818:Animals; D002112:Calcifediol / Q000097:blood; D002116:Calcitonin / Q000097:blood; D002117:Calcitriol / Q000097:blood; D002118:Calcium / Q000097:blood / Q000493:pharmacokinetics; D002762:Cholecalciferol / Q000008:administration & dosage* / Q000009:adverse effects*; D019587:Dietary Supplements / Q000009:adverse effects; D004285:Dogs / Q000254:growth & development*; D005260:Female; D013006:Growth Hormone / Q000097:blood; D006132:Growth Plate / Q000033:anatomy & histology / Q000254:growth & development; D007334:Insulin-Like Growth Factor I / Q000032:analysis; D007408:Intestinal Absorption; D007668:Kidney / Q000502:physiology; D008297:Male; D008657:Metabolic Clearance Rate; D010012:Osteogenesis / Q000187:drug effects*; D010281:Parathyroid Hormone / Q000097:blood; D010710:Phosphates / Q000097:blood; D018167:Receptors, Calcitriol / Q000032:analysis
D010281:Parathyroid Hormone; D010710:Phosphates; D018167:Receptors, Calcitriol; D002762:Cholecalciferol; D015650:24,25-Dihydroxyvitamin D 3; D007334:Insulin-Like Growth Factor I; D013006:Growth Hormone; D002116:Calcitonin; D002117:Calcitriol; D002112:Calcifediol; D002118:Calcium